I think from what I recall of reading the law and the incorporation in Nevada, a proxy vote has to be made for increase in shares authorized and also for a sale of the company.

I believe both are taking place since Pasaca is getting 51% in the transaction.

Of course their not here to make our dreams.

I just think the play is larger than just them hedging a $4.5 million loan on the hopes that the announcement drives up the share price for a non-reporting company so they can convert notes and sell shares for the profit. Sounds like a risking maneuver in my opinion.

Do they just get consulting fees? What other avenues are available to profit from QMC's success?

What if they make QMC successful, dividends would be a good way to return their investment as 51% common shares owner.

Don’t we all, but for $15 million, I got to think there’s more potential in other projects. Who just throws $15 million at a company without expecting great or huge returns?

It does appear to be that the brakes are being applied to keep the gains to 10-30% daily.

But I don’t mind as long it’s going up! ;)

Hopefully QMC will get those damn financial released and give us more of an update on status of business well before they have the shareholder vote.

Valid point.

Someone posted a week ago or so that they hit 100+ downloads.

So we don’t know what was downloaded for the event in France.

The next threshold is 500+.

Guess we’ll wait and see how long it takes to get to 500+.

Stand corrected. Missed that

Yes, this is the test Innova licensed or is distributing and has been delivering to the UK.

Yep, old school, lol

https://www.360dx.com/policy-legislation/biden-administration-finalizing-six-contracts-increase-home-sars-cov-2-testing?utm_nl_name=coronavirus-bulletin&utm_source=Sailthru&utm_medium=email&utm_campaign=360Dx%20Coronavirus%20-%20Sat%202021-02-06&utm_term=Coronavirus%20Bulletin#.YCFtYmQ8KEe

Have you talked to anyone about their experience trying to get vaccinated? It’s not easy.

My mother-in-law who’s 70 in Florida can’t get one even when she’s on the first round candidate list.

Also, I’m sure your aware that the vaccine doesn’t prevent the virus, just reduces symptoms to the point that very few would be hospitalized. At least, that’s my understanding of the trial info. People vaccinated could still be spreaders, although the risk is lower, from what I understand.

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Search for Biotime. That's the LFT they licensed.

My number was based on $15 million in revenue even though I spoke of potential. Share price is most often a reflection of future value or earnings, is it not?

I just read the potential in the agreement differently than some, which is apparently clear by the discussions here. Sounds like QMC is supply nano particles (my interpretation of words in agreement) and has a qdot test kit (Dr. Malan brochure on LinkedIn) in development or developed with Pasaca bringing manufacturing capabilities and capital to the equation.

Enjoy the rest of your Sunday!

Well at least we came up with one of the same numbers, $0.75, however via different calculations.

If Pasaca and Squires to manage to sign more sales contacts, how is selling any of us short by 50% a bad thing for anyone if Pasaca brings the level of needed capital that QMC had failed to attract before now.

Say that $15 million turns into $150 million this year? Was selling half of the company better for all investors?

Is selling our half to gain ten times better than keeping half of nothing?

Not accounting debt and only revenue, 15million divided by 1.5 billion is 0.01 cents. Of course, what’s the profit margin? Let’s assume 25% and pick a market multiplier, let’s say 30, you have $0.075. Use 100 and you get $0.25.

What’s their future potential if their supplying nano particles and/or get royalties from QMC HealthID?

What is additional contracts are announce in the coming weeks associated with their business with Pasaca, etc.? Where should the price target be then?

What if financial statements are filed as anticipated to get them back to compliant?

What will all these things do to investor sentiment and price target?

Again, you’re realistic price target isn’t everyone’s.

What about $15 million in revenue? We don’t know when that hits the books, but it’s guaranteed future cash flow.

I don’t get it. The MM is there to add liquidity not regulate price. What you just said was they were there to regulate a realistic price?

They stepped in to add liquidity at 3-6 times the average to keep the price at a realistic price that they determined to be realistic?

Per my calculation or what is known about the deal, revenue, and outstanding shares, we should be around $0.20 per share right now assuming the agreement had all current details about outstanding and other shares.

So what is realistic?

Do you really think the market needed help with liquidity the past week? We hit 3 - 6 times the average daily volume. Looks like the short was 60% of that volume.

Looks like FINRA tracks it based on the graph info.

https://www.finra.org/#/

The other company EUA was linked on Medek’s website for the antigen test.

I don’t. Simply pointing to the fact the tech exist and ready for sale. Just don’t know who.

Clearly there appears to be a couple. The point being that the tech is already developed if they license it.

Ted made a point about Dr. Malan saying developing, if I recall the quote correctly.

Found the EUA for this kit and the company it was issued to was Access Bio, Inc., not King Focus.

It may have already been developed and they aren’t just licensing someone else’s tech. I think someone else posted this company. They also call it QDTK. Looks to be same little likely from King Focus.

https://medekhealth.com/fda-authorized-covid19-antigen-test-kits

I think based on his pdf, they have a test and are developing other tests, but clearly we’re all guessing at this point.

You do realize they haven’t filed financials in almost 2 years! ;)

If Pasaca doesn’t have 5% of the company, then there would be no filing for the loan itself. We’d have to wait to see it in a quarterly or annual report.

Oops! Error on my part in understanding issued and outstanding shares. Read up to correct that error!

Have a great day!

Thanks, Ted. Just educated myself on what outstanding shares actually included. I was understanding it all wrong.

They provide the updated share count in the Securities Purchase and Financing Agreement filed with the SEC the other day which included all outstanding warrants and options.

Doing a little Google snooping, I found some of these items while looking for the "True-Dot" name.

Well, they could! Lol ;)

Around minute 46 is a good start.

Because after listening to things like this, it’s not so obvious.

It definitely crossed my mind! ;)

Valid statement as I merged them to a point.

Lol! Not ranting, simply making an opinion known.

I think it’s a fact that they would be viewed to have less risk to many investors if they weren’t delinquent and their financial status was fully public.

My measure is access to the market. Clearly there are many brokers still allowing trades, but one the largest is not.

Fidelity has about 1/3 of the total accounts when compared to the top five firms. I think having a large portion of traders having to move accounts to trade QMC is a liquidity issue.

Top Five Brokers:

----------------AUM-----Accounts
------------(trillion)--(million)
Vanguard--------$6.20---30
Charles Schwab--$4.10---14.1
Fidelity--------$3.31---29.6
TD Ameritrade---$1.32---11.5
E Trade---------$0.35---5.2

https://www.brokerage-review.com/online-brokers/best-brokerage-firms.aspx#:~:text=The%203%20best%20brokerage%20companies,highest%20quality%20of%20investment%20services&text=In%202021%2C%20we%20named%20TD,%2Dit%2Dyourself)%20investors.

Fidelity is a big fat goose egg when trying to buy. I just tried to verify.

“(TC9052)Opening transactions for Pink Sheets (without information) are not permitted because of the risks associated with these securities and all Microcap securities.”

I’ve no clue about short selling under individual MM.

But I do know we suffer from a liquidity issue right now caused by delinquent financial statements, thereby being on the OTC pink sheets.

I know for a fact that some brokers won’t let people buy QTMM right now while they are on the pink sheets. But they all will let you sell while on pink sheets, to my knowledge.

But venture capitalist do take their company’s they created public. Innova would be an example of a future IPO for Pasaca.